The Hidden Link Between Lyme Disease and Alzheimer's (The MSIDS Protocol)

0:00The anti-amyloid monoclonal antibodies like lacanamab, denanamab that are out there, they lower P-Tau by about 23% over six years.

0:09We lowered it by 63% in nine weeks.

0:12The reason being the amyloid that was being produced in the brain, so the phosphorylated tau, was coming from an infection.

0:19Hey, this is Ari.

0:20Welcome back to the Energy Blueprint podcast.

0:22With me in this episode is Dr.

0:24Richard Horowitz, who is a board-certified internist and medical director of the Hudson Valley Healing Arts Center, an integrated medical center which combines both mainstream and integrative approaches in the treatment of Lyme disease and other tick-borne disorders.

0:39He's treated over 13,000 Lyme and tick-borne disease patients over the last four decades, with patients coming from all over the world to his clinic.

0:49And he's advised the HHS, the New York State Department of Health, as well as governmental agencies all over the world.

0:57His third book, titled Ending Chronic Illness, is coming out in October of this year, 2026.